Colesevelam hydrochloride: Reducing atherosclerotic coronary heart disease risk factors

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 733-742

  Bays, Harold ^a   Jones, Peter H ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cholesterol; Colesevelam HC1; Coronary heart disease; Diabetes mellitus; Glucose; Lipids

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DIGITALIS; DIGOXIN; DIURETIC AGENT; ESTROGEN; EZETIMIBE; FENOFIBRATE; GLUCOSE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METOPROLOL; MEVINOLIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PLACEBO; QUINIDINE; SITAGLIPTIN; SULFONYLUREA; SUMATRIPTAN; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

ATHEROSCLEROSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CORONARY RISK; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REMISSION; REVIEW; RISK REDUCTION;

ALLYLAMINE; ANIMALS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CORONARY DISEASE; HUMANS; LIPID METABOLISM; RISK FACTORS;

EID: 36148996795     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Baigent C, Keech A, Kearney PM, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366:1267-78.
2. Bariciak ED, Plint AC, Gaboury I, et al. 2003. Dating of bruises in children: an assessment of physician accuracy. Pediatrics, 112:804-7.
3. Bays H. 2002. Ezetimibe. Expert Opin Investig Drugs, 11: 1587-1604.
4. Bays HE. 2004. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther, 2:485-501.
5. Bays H. 2006a. Adiposopathy - defining, diagnosing, and establishing indications to treat "sick fat": what are the regulatory considerations? US Endocrine Disease, 12-14.
6. Bays H. 2006b. What are the long-term effects of statin therapy? Nat Clin Pract Cardiovasc Med, 3:128-9.
7. Bays H. 2006c. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol, 97:6C-26C.
8. Bays H, Abate N, Chandalia M. 2005. Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiology, 1:39-59.
9. Bays H, Ballantyne C. 2006. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidology, 1:389-420.
10. Bays H, Blonde L, Rosenson R. 2006c. Adiposopathy: How do diet, exercise, weight loss and drug therapies improve metabolic disease? Expert Rev Cardiovasc Dier, 4:871-95.
11. Bays HE, Cohen DE. 2007. Rationale and design of a prospective clinical trial program to evaluate colesevelam's glucose-lowering effects in patients with type 2 diabetes mellitus. Curr Med Res Opin, 23:1673-84.
12. Bays HE, Davidson M, Jones MR, et al, 2006b. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol, 97:1198-1205.
13. Bays H, Dujovne C. 2003. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother, 4:779-90.
14. Bays HE, Dujovne CA, McGovern ME, et al. 2003. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and sinivastatin. the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]. Am J Cardiol, 91:667-72.
15. Bays H, Dujovne CA. 2006. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep, 8:144-56.
16. Bays HE, Goldberg RB, Truitt K, et al. 2007. Addition of colesevelam HCl to patients with type 2 diabetes mellitus inadequately controlled on a metformin-based therapy improves glycemic control. Abstract poster Presentation American Association of Clinical Endocrinologists 16th Annual Meeting and Clinical Congress, Seattle Washington USA; April 14, 2007.
17. Bays HE, Ose L, Fraser N, et al. 2004. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther, 26:1758-73.
18. Bays H, Rhyne J, Abby S, et al. 2006a. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin, 22:2191-200.
19. Bays H, Stein EA. 2003. Pharmacotherapy for dyslipidaemia - current therapies and future agents. Expert Opin Pharmacother, 4:1901-38.
20. Blankenhorn DH, Nessim SA, Johnson RL, et al. 1987. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA, 257:3233-40.
21. Brendel C, Schoonjans K, Botrugno OA, et al. 2002. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol, 16:2065-76.
22. Brensike JF, Levy RI, Kelsey SF, et al. 1984. Effects of therapy with
23. cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation, 69:313-24.
24. Brown G, Albers JJ, Fisher LD, et al. 1990. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med, 323:1289-98.
25. Cao G, Liang Y, Broderick CL, et al. 2003. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem, 278:1131-6.
26. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. 1990. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA, 264:3013-17.
27. Davidson MH. 2006. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care, 12:S405-S11.
28. Davidson MH, Maki KC, Pearson TA, et al. 2005. Results of the National Cholesterol Education. NCEP. Program Evaluation ProjecT Utilizing Novel E-Technology. NEPTUNE. II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol, 96:556-63.
29. Devaraj S, Autret B, Jialal I. 2006. Effects of colesevelam hydrochloride. WelChol, on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol, 98:641-3.
30. Efanov AM, Sewing S, Bokvist K, et al. 2004. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes, 53(Suppl 3):S75-S8.
31. Flexman AM, Del VG, Schwarz SK. 2007. Dark green blood in the operating theatre. Lancet, 369:1972.
32. Fonseca V, Rosenstock J, Truitt K, et al. 2007. Colesevelam HCl added to sulfonylurea-based therapy in patients with inadequately controlled type 2 diabetes mellitus improves glycemic control. Abstract poster presentation American Association of Clinical Endocrinologists 16th Annual Meeting and Clinical Congress, Seattle Washington USA. April 14th, 2007.
33. Fu L, John LM, Adams SH, et al. 2004. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology, 145:2594-603.
34. Gagne C, Bays HE, Weiss SR, et al. 2002. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol, 90:1084-91.
35. Garg A, Grundy SM. 1994. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med, 121:416-22.
36. Goldberg RB, Truitt K. 2006. Colesevelam HCl improves glycemic control in type 2 diabetes mellitus subjects managed with insulin therapy. Abstract poster presentation. American Heart Association Annual Meeting, Chicago Illinois USA; November 12-15, 2006.
37. Grundy SM, Cleeman JI, Merz CN, et al. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110:227-39.
38. Gupta S, Pandak WM, Hylemon PB. 2002. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem Biophys Res Commun, 293:338-43.
39. Hofmann AF. 1999. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med, 159:2647-58.
40. Holt JA, Luo G, Billin AN, et al. 2003. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev, 17:1581-91.
41. Januvia. 2007. Stagliptin [online]. URL: http://www.januvia.com.
42. Jones P, Kafonek S, Laurora I, et al. 1998. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia, the CURVES study. Am J Cardiol, 81:582-7.
43. Jones PH. 2006. Rationale for intensive statin treatment in high-risk patients. Prev Cardiol, 9:91-5.
44. Kane JP, Malloy MJ, Ports TA, et al. 1990. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA, 264:3007-12.
45. Kerr TA, Saeki S, Schneider M, et al. 2002. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell, 2:713-20.
46. Laffitte BA, Chao LC, Li J, et al. 2003. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA, 100:5419-24.
47. Lipid Research Clinics. 1984a. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA, 251:351-64.
48. Lipid Research Clinics. 1984b. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 251:365-74.
49. Lundasen T, Galman C, Angelin B, et al. 2006. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med, 260:530-6.
50. Ma K, Saha PK, Chan L, et al. 2006. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest, 116:1102-9.
51. McKenney J, Jones M, Abby S. 2005. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin, 21:1403-12.
52. Mitro N, Mak PA, Vargas L, et al. 2007. The nuclear receptor LXR is a glucose sensor. Nature, 445:219-23.
53. [NCEP] National Cholesterol Education Program. 2002. Third Report of the National Cholesterol Education Program. NCEP. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III. final report. Circulation, 106:3143-421.
54. Seo JB, Moon BM, Kim WS, et al. 2004. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol, 24:3430-44.
55. Shibata S, Hayakawa K, Egashira Y, et al. 2007. Roles of nuclear receptors in the up-regulation of hepatic cholesterol 7alpha-hydroxylase by cholestyramine in rats. Life Sci, 80:546-53.
56. Stayrook KR, Bramlett KS, Savkur RS, et al. 2005. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology, 146:984-91.
57. Strack AM, Myers RW. 2004. Modulation of metabolic syndrome by fibroblast growth factor 19. FGF19? Endocrinology, 145:2591-3.
58. Stulnig TM, Oppermann U, Steffensen KR, et al. 2002. Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes, 51:2426-33.
59. Tonstad S. 2000. Role of lipid-lowering pharmacotherapy in children. Paediatr Drugs, 2:11-22.
60. Tontonoz P, Mangelsdorf DJ. 2003. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol, 17:985-93.
61. Vasudevan AR, Jones PH. 2006. Effective use of combination lipid therapy. Curr Atheroscler Rep, 8:76-84.
62. Watts GF, Lewis B, Brunt JN, et al. 1992. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study. STARS. Lancet, 339:563-9.
63. Welchol® Product Information. 2007. Cholesevelam hydrochloride. Accessed July 1, 2007. URL: http://www.welchol.com/pdfs/fullPI.pdf
64. Yamakawa T, Takano T, Utsunomiya H, et al. 2007. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J, 54:53-8.
65. Zhang Y, Lee FY, Barrera G, et al. 2006. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA, 103:1006-11.
66. Zieve FJ, Kalin MF, Schwartz SL, et al. 2007. Results of the glucose-lowering effect of WelChol study. GLOWS: A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther, 29:74-83.